Liesbet Deprez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Liesbet Deprez has a total of 337 co-authors. Here are the top co-authors by number of shared publications:
- Jurgen Del-Favero
Multiplicom N.V., Niel, Belgium
8 shared publications - Kristl G. Claeys
Department of Neurology University Hospitals Leuven Leuven Belgium
8 shared publications - Dirk Goossens
Multiplicom N.V., Niel, Belgium
7 shared publications Arvid Suls
Neurogenetics Group, VIB‐Department of Molecular Genetics, University Hospital of Antwerp, Antwerp, Belgium
6 shared publications- Lucia Renee Ruhaak
Department of Clinical Chemistry and Laboratory Medicine , Leiden University Medical Center , Leiden , The Netherlands
6 shared publications - Peter De Jonghe
A Neurogenetics Group, Center for Molecular Neurology , VIB , Antwerp , Belgium
6 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (9) , 960-972
Correlation and Commutability Study between an LC-MS-Based Reference Measurement Procedure and Immunoassays Measuring Apolipoprotein A-I and Apolipoprotein B
Background: Serum concentrations of apolipoprotein A-I (ApoA-I) and apolipoprotein B (ApoB) can have a predictive value for cardiovascular events beyond the traditional lipid profile. The IFCC Working Group on Apolipoproteins by Mass Spectrometry is developing a novel reference measurement system for seven clinically relevant apolipoproteins, including ApoA-I and ApoB. The system will consist of a multiplex mass spectrometry–based reference measurement procedure (RMP) and commutable secondary reference materials (RMs). Methods: Agreement between the RMP and 8 immunoassay-based measurement procedures (MPs) was investigated using 30 clinical samples. Furthermore, the commutability of 8 candidate RMs, consisting of frozen serum pools, and the existing WHO-IFCC standards SP1-01 and SP3-08 was assessed. Results: The harmonization level among eight immunoassay-based MPs for ApoA-I and ApoB still needs improvement. The RMP results showed a good correlation with results of the immunoassay-based MPs for both ApoA-I and ApoB. For ApoA-I, 7 candidate RMs showed good commutability, while SP1-01 and one candidate RM showed potential noncommutability for one method comparison. For ApoB, the commutability profile of the candidate RMs was more variable, and SP3-08 showed noncommutability for several method comparisons. Conclusions: The RMP and the immunoassay-based MPs have comparable selectivity for ApoA-I and ApoB, and a well-established reference measurement system can lead to improved harmonization. Future commutable secondary RMs can be based on frozen human serum pools; however, for ApoB, preselection of single-donor samples might be needed to limit the impact of sample-specific effects.
- 17 June 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (9) , 960-972
Open AccessCorrelation and Commutability Study between an LC-MS-Based Reference Measurement Procedure and Immunoassays Measuring Apolipoprotein A-I and Apolipoprotein B
Background: Serum concentrations of apolipoprotein A-I (ApoA-I) and apolipoprotein B (ApoB) can have a predictive value for cardiovascular events beyond the traditional lipid profile. The IFCC Working Group on Apolipoproteins by Mass Spectrometry is developing a novel reference measurement system for seven clinically relevant apolipoproteins, including ApoA-I and ApoB. The system will consist of a multiplex mass spectrometry–based reference measurement procedure (RMP) and commutable secondary reference materials (RMs). Methods: Agreement between the RMP and 8 immunoassay-based measurement procedures (MPs) was investigated using 30 clinical samples. Furthermore, the commutability of 8 candidate RMs, consisting of frozen serum pools, and the existing WHO-IFCC standards SP1-01 and SP3-08 was assessed. Results: The harmonization level among eight immunoassay-based MPs for ApoA-I and ApoB still needs improvement. The RMP results showed a good correlation with results of the immunoassay-based MPs for both ApoA-I and ApoB. For ApoA-I, 7 candidate RMs showed good commutability, while SP1-01 and one candidate RM showed potential noncommutability for one method comparison. For ApoB, the commutability profile of the candidate RMs was more variable, and SP3-08 showed noncommutability for several method comparisons. Conclusions: The RMP and the immunoassay-based MPs have comparable selectivity for ApoA-I and ApoB, and a well-established reference measurement system can lead to improved harmonization. Future commutable secondary RMs can be based on frozen human serum pools; however, for ApoB, preselection of single-donor samples might be needed to limit the impact of sample-specific effects.
- Open Access
- 18 April 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (7) , 791-800
Transferability and Between Laboratory Imprecision of an LC-MS/MS-Based Reference Measurement Procedure for Apolipoproteins
Background: Apolipoprotein standardization in multiple calibration laboratories requires equivalent results to value assign matrix-based reference and external quality assurance materials. A multiplexed LC-MS/MS-based reference measurement procedure (RMP) has been developed for serum apolipoproteins apo(a), apoA-I, apoB, apoC-I, apoC-II, apoC-III, and apoE. This study evaluates the transferability of the RMP between 3 calibration labs and determines the between-laboratory imprecision. Methods: Six periodic ring trial surveys were held. The study protocol, calibrators, internal standards, quality controls (QCs), and clinical samples (CSs) were shared among the laboratories. Intra-laboratory imprecision and inter-peptide comparisons evaluated intra-laboratory performance, while inter-laboratory imprecision evaluated equivalence between the calibration labs. Precision of the common bilevel QC monitored the level of harmonization over time. Results: Intra-laboratory imprecision fulfilled predefined analytical performance, defined as repeatability <50% of the maximum allowable uncertainty (MAU) at minimal criteria. Median interlaboratory variation (CVbl) was 3.71%, 3.33%, 7.38%, 6.74%, 3.88%, and 3.90% for apoA-I, apoB, apoC-I, apoC-II, apoC-III, and apoE, respectively. For apo(a), CVbl was concentration (x) dependent following 206.32×x−0.899%. In QC samples, the average imprecision for all apolipoproteins decreased from 6.0% and 18.1% for QC1 and QC2, to 5.2% and 9.5%, indicating improvement of analytical performance of the network over time. Conclusions: This study shows the feasibility of transferring the multiplex apo LC-MS/MS-based RMP between laboratories. Predefined performance specifications were fulfilled for all seven apolipoproteins. Ongoing round-robin studies will ensure stable performance of the calibration labs required to accomplish an accurate value-base for apolipoprotein certification of commercial reagents.
- 18 April 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (7) , 791-800
Open AccessTransferability and Between Laboratory Imprecision of an LC-MS/MS-Based Reference Measurement Procedure for Apolipoproteins
Background: Apolipoprotein standardization in multiple calibration laboratories requires equivalent results to value assign matrix-based reference and external quality assurance materials. A multiplexed LC-MS/MS-based reference measurement procedure (RMP) has been developed for serum apolipoproteins apo(a), apoA-I, apoB, apoC-I, apoC-II, apoC-III, and apoE. This study evaluates the transferability of the RMP between 3 calibration labs and determines the between-laboratory imprecision. Methods: Six periodic ring trial surveys were held. The study protocol, calibrators, internal standards, quality controls (QCs), and clinical samples (CSs) were shared among the laboratories. Intra-laboratory imprecision and inter-peptide comparisons evaluated intra-laboratory performance, while inter-laboratory imprecision evaluated equivalence between the calibration labs. Precision of the common bilevel QC monitored the level of harmonization over time. Results: Intra-laboratory imprecision fulfilled predefined analytical performance, defined as repeatability <50% of the maximum allowable uncertainty (MAU) at minimal criteria. Median interlaboratory variation (CVbl) was 3.71%, 3.33%, 7.38%, 6.74%, 3.88%, and 3.90% for apoA-I, apoB, apoC-I, apoC-II, apoC-III, and apoE, respectively. For apo(a), CVbl was concentration (x) dependent following 206.32×x−0.899%. In QC samples, the average imprecision for all apolipoproteins decreased from 6.0% and 18.1% for QC1 and QC2, to 5.2% and 9.5%, indicating improvement of analytical performance of the network over time. Conclusions: This study shows the feasibility of transferring the multiplex apo LC-MS/MS-based RMP between laboratories. Predefined performance specifications were fulfilled for all seven apolipoproteins. Ongoing round-robin studies will ensure stable performance of the calibration labs required to accomplish an accurate value-base for apolipoprotein certification of commercial reagents.
- Open Access
- 21 March 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (7) , 1315-1326
Antiphospholipid IgG Certified Reference Material ERM ® -DA477/IFCC: a tool for aPL harmonization?
Objectives: The Certified Reference Material (CRM) ERM ® -DA477/IFCC is a new polyclonal IgG anti-beta2-glycoprotein I (anti-β2GPI) material for the harmonization of the laboratory diagnosis of antiphospholipid syndrome (APS). We evaluated CRM’s ability to represent the heterogeneity of APS patient anti-β2GPI antibodies and to calibrate IgG anti-β2GPI methods. Methods: We characterized CRM for its reactivity against domain-1, using the QUANTA Flash ® β2GPI-domain-1 assay, and against domains-4-5 of β2GPI, and single-domain-deleted β2GPI molecules using in-house ELISAs. We used QUANTA Lite ® ELISA, QUANTA Flash ® CLIA, and EliA™ FEIA methods to evaluate the CRM’s anti-Cardiolipin (anti-CL) activity. Four anti-β2GPI IgG methods (in-house and QUANTA Lite ® ELISA, QUANTA Flash ® CLIA, and EliA™ FEIA) were also used to evaluate the CRM’s calibration efficacy, alongside 133 clinical samples (CSs) and 99 controls. Results: The CRM showed high anti-domain-1 activity and no anti-domain-4-5 activity at the recommended assay dilution. The domain-dependent-β2GPI reactivity profiles were comparable with full-blown APS. There was acceptable dilution linearity for anti-CL assays with R 2 ranging from 0.957 to 0.997. For the four anti-β2GPI IgG assays, calibration with the CRM led to a good comparability of the average result of CSs for two of the assays. New cut-offs calculated from this work improved comparability in quantitative results between three of the assays: 85 % concordance with CRM compared to 66 % concordance with assay-specific-calibration. Conclusions: The CRM is representative of patient anti-β2GPI/CL heterogeneity and should improve anti-β2GPI IgG method harmonization. However, the level of achievable method harmonization is affected by differences in the selectivity among the assays.
- 21 March 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (7) , 1315-1326
Open AccessAntiphospholipid IgG Certified Reference Material ERM ® -DA477/IFCC: a tool for aPL harmonization?
Objectives: The Certified Reference Material (CRM) ERM ® -DA477/IFCC is a new polyclonal IgG anti-beta2-glycoprotein I (anti-β2GPI) material for the harmonization of the laboratory diagnosis of antiphospholipid syndrome (APS). We evaluated CRM’s ability to represent the heterogeneity of APS patient anti-β2GPI antibodies and to calibrate IgG anti-β2GPI methods. Methods: We characterized CRM for its reactivity against domain-1, using the QUANTA Flash ® β2GPI-domain-1 assay, and against domains-4-5 of β2GPI, and single-domain-deleted β2GPI molecules using in-house ELISAs. We used QUANTA Lite ® ELISA, QUANTA Flash ® CLIA, and EliA™ FEIA methods to evaluate the CRM’s anti-Cardiolipin (anti-CL) activity. Four anti-β2GPI IgG methods (in-house and QUANTA Lite ® ELISA, QUANTA Flash ® CLIA, and EliA™ FEIA) were also used to evaluate the CRM’s calibration efficacy, alongside 133 clinical samples (CSs) and 99 controls. Results: The CRM showed high anti-domain-1 activity and no anti-domain-4-5 activity at the recommended assay dilution. The domain-dependent-β2GPI reactivity profiles were comparable with full-blown APS. There was acceptable dilution linearity for anti-CL assays with R 2 ranging from 0.957 to 0.997. For the four anti-β2GPI IgG assays, calibration with the CRM led to a good comparability of the average result of CSs for two of the assays. New cut-offs calculated from this work improved comparability in quantitative results between three of the assays: 85 % concordance with CRM compared to 66 % concordance with assay-specific-calibration. Conclusions: The CRM is representative of patient anti-β2GPI/CL heterogeneity and should improve anti-β2GPI IgG method harmonization. However, the level of achievable method harmonization is affected by differences in the selectivity among the assays.
- Open Access
- 4 February 2025
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 417 (12) , 2617-2627
Commutability study on three CRMs evaluating their suitability for calibration, trueness verification and statistical quality control of methods measuring metal concentrations in human blood
The commutability of three certified reference materials for Cd, Cr, Hg, Ni, Pb and Tl in blood was evaluated for the combination of digestion ICP-MS with dilution ICP-MS or dilution GFAAS using the difference in bias approach. Maximum non-commutability bias (MANCB) was derived from the median of the tolerance limits set by six proficiency testing (PT) providers. The evaluation showed that this criteria are too strict and that either unfeasible high number of measurements or a larger MANCB is required to demonstrate commutability. The effect of increasing the MANCB on the maximum tolerable measurement uncertainty was found small to moderate demonstrating the commutability of the materials when used as a calibrator. Also the inclusion of the uncertainty of non-commutability into the measurement uncertainty resulted in only small increases of the measurement uncertainty, demonstrating the suitability of the materials for trueness control and method validation. The bias of the three CRMs was for most elements within the 99% confidence limits of the bias of the patient samples, demonstrating the suitability of the materials for statistical quality control. Graphical abstract
- 4 February 2025
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 417 (12) , 2617-2627
Open AccessCommutability study on three CRMs evaluating their suitability for calibration, trueness verification and statistical quality control of methods measuring metal concentrations in human blood
The commutability of three certified reference materials for Cd, Cr, Hg, Ni, Pb and Tl in blood was evaluated for the combination of digestion ICP-MS with dilution ICP-MS or dilution GFAAS using the difference in bias approach. Maximum non-commutability bias (MANCB) was derived from the median of the tolerance limits set by six proficiency testing (PT) providers. The evaluation showed that this criteria are too strict and that either unfeasible high number of measurements or a larger MANCB is required to demonstrate commutability. The effect of increasing the MANCB on the maximum tolerable measurement uncertainty was found small to moderate demonstrating the commutability of the materials when used as a calibrator. Also the inclusion of the uncertainty of non-commutability into the measurement uncertainty resulted in only small increases of the measurement uncertainty, demonstrating the suitability of the materials for trueness control and method validation. The bias of the three CRMs was for most elements within the 99% confidence limits of the bias of the patient samples, demonstrating the suitability of the materials for statistical quality control. Graphical abstract
- Open Access
- 16 December 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 567, 120097
Recommendations for assessing commutability of a replacement batch of a secondary calibrator certified reference material
- 16 December 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 567, 120097
Open AccessRecommendations for assessing commutability of a replacement batch of a secondary calibrator certified reference material
- Open Access
- 19 June 2023
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 62 (1) , 50-59
Comparison and commutability study among four faecal immunochemical tests (FIT) systems
Objectives: Faecal immunochemical tests for haemoglobin (FIT) are used in colorectal cancer screening programs around the world and increasingly for triage of symptomatic patients. FIT results are currently not traceable to a common reference standard and results obtained on various FIT systems may not be equivalent. The size of the bias between the systems is difficult to quantify due to the complex pre-analytical aspects of FIT. Methods: This study aimed to quantify the bias and the correlation between four FIT systems by measuring a panel of 38 faecal samples while limiting the effect of the pre-analytical aspects. In addition, the commutability of seven candidate reference materials (RM) was assessed. Results: Pairwise method comparisons based on faecal samples demonstrated Pearson correlation coefficients ranging between 0.944 and 0.970 and an average proportional bias of −30 to −35 % for one FIT system compared to the other three. The relative standard deviation among biases of the individual samples was around 20 %. Due to these sample specific differences, no decisive conclusions could be drawn in the commutability study. However, two candidate RMs, prepared in the FIT system-specific storage/extraction buffers, had a better commutable profile than the other five. Conclusions: The use of a common threshold for all FIT systems is currently not possible due to the presence of a proportional bias. We have identified potential commutable RMs to take to further studies on the production of a common calibrator, with the aim being to reduce the analytical bias observed on different FIT systems.
- 19 June 2023
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 62 (1) , 50-59
Open AccessComparison and commutability study among four faecal immunochemical tests (FIT) systems
Objectives: Faecal immunochemical tests for haemoglobin (FIT) are used in colorectal cancer screening programs around the world and increasingly for triage of symptomatic patients. FIT results are currently not traceable to a common reference standard and results obtained on various FIT systems may not be equivalent. The size of the bias between the systems is difficult to quantify due to the complex pre-analytical aspects of FIT. Methods: This study aimed to quantify the bias and the correlation between four FIT systems by measuring a panel of 38 faecal samples while limiting the effect of the pre-analytical aspects. In addition, the commutability of seven candidate reference materials (RM) was assessed. Results: Pairwise method comparisons based on faecal samples demonstrated Pearson correlation coefficients ranging between 0.944 and 0.970 and an average proportional bias of −30 to −35 % for one FIT system compared to the other three. The relative standard deviation among biases of the individual samples was around 20 %. Due to these sample specific differences, no decisive conclusions could be drawn in the commutability study. However, two candidate RMs, prepared in the FIT system-specific storage/extraction buffers, had a better commutable profile than the other five. Conclusions: The use of a common threshold for all FIT systems is currently not possible due to the presence of a proportional bias. We have identified potential commutable RMs to take to further studies on the production of a common calibrator, with the aim being to reduce the analytical bias observed on different FIT systems.
- Open Access
- 16 January 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (3) , 251-261
Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests
Background: Medical results generated by European CE Marking for In Vitro Diagnostic or in-house tests should be traceable to higher order reference measurement systems (RMS), such as International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)-endorsed reference measurement procedures (RMPs) and reference materials. Currently, serum apolipoprotein (a) [apo(a)] is recognized as a novel risk factor for cardiovascular risk assessment and patient management. The former RMS for serum apo(a) is no longer available; consequently, an International System of Units (SI)-traceable, ideally multiplexed, and sustainable RMS for apo(a) is needed.Methods: A mass spectrometry (MS)-based candidate RMP (cRMP) for apo(a) was developed using quantitative bottom-up proteomics targeting 3 proteotypic peptides. The method was provisionally validated according to ISO 15193 using a single human serum based calibrator traceable to the former WHO-IFCC RMS.Results: The quantitation of serum apo(a) was by design independent of its size polymorphism, was linear from 3.8 to 456 nmol/L, and had a lower limit of quantitation for apo(a) of 3.8 nmol/L using peptide LFLEPTQADIALLK. Interpeptide agreement showed Pearson Rs of 0.987 and 0.984 for peptides GISSTVTGR and TPENYPNAGLTR, and method comparison indicated good correspondence (slopes 0.977, 1.033, and 1.085 for LFLEPTQADIALLK, GISSTVTGR, and TPENYPNAGLTR). Average within-laboratory imprecision of the cRMP was 8.9%, 11.9%, and 12.8% for the 3 peptides.Conclusions: A robust, antibody-independent, MS-based cRMP was developed as higher order RMP and an essential part of the apo(a) traceability chain and future RMS. The cRMP fulfils predefined analytical performance specifications, making it a promising RMP candidate in an SI-traceable MS-based RMS for apo(a).
- 16 January 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (3) , 251-261
Open AccessDevelopment of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests
Background: Medical results generated by European CE Marking for In Vitro Diagnostic or in-house tests should be traceable to higher order reference measurement systems (RMS), such as International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)-endorsed reference measurement procedures (RMPs) and reference materials. Currently, serum apolipoprotein (a) [apo(a)] is recognized as a novel risk factor for cardiovascular risk assessment and patient management. The former RMS for serum apo(a) is no longer available; consequently, an International System of Units (SI)-traceable, ideally multiplexed, and sustainable RMS for apo(a) is needed.Methods: A mass spectrometry (MS)-based candidate RMP (cRMP) for apo(a) was developed using quantitative bottom-up proteomics targeting 3 proteotypic peptides. The method was provisionally validated according to ISO 15193 using a single human serum based calibrator traceable to the former WHO-IFCC RMS.Results: The quantitation of serum apo(a) was by design independent of its size polymorphism, was linear from 3.8 to 456 nmol/L, and had a lower limit of quantitation for apo(a) of 3.8 nmol/L using peptide LFLEPTQADIALLK. Interpeptide agreement showed Pearson Rs of 0.987 and 0.984 for peptides GISSTVTGR and TPENYPNAGLTR, and method comparison indicated good correspondence (slopes 0.977, 1.033, and 1.085 for LFLEPTQADIALLK, GISSTVTGR, and TPENYPNAGLTR). Average within-laboratory imprecision of the cRMP was 8.9%, 11.9%, and 12.8% for the 3 peptides.Conclusions: A robust, antibody-independent, MS-based cRMP was developed as higher order RMP and an essential part of the apo(a) traceability chain and future RMS. The cRMP fulfils predefined analytical performance specifications, making it a promising RMP candidate in an SI-traceable MS-based RMS for apo(a).
- Open Access
- 16 January 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (3) , 262-272
Commutability Assessment of Candidate Reference Materials for Lipoprotein(a) by Comparison of a MS-based Candidate Reference Measurement Procedure with Immunoassays
Background: Elevated concentrations of lipoprotein(a) [Lp(a)] are directly related to an increased risk of cardiovascular diseases, making it a relevant biomarker for clinical risk assessment. However, the lack of global standardization of current Lp(a) measurement procedures (MPs) leads to inconsistent patient care. The International Federation for Clinical Chemistry and Laboratory Medicine working group on quantitating apolipoproteins by mass spectrometry (MS) aims to develop a next-generation SI (International system of units)-traceable reference measurement system consisting of a MS-based, peptide-calibrated reference measurement procedure (RMP) and secondary serum-based reference materials (RMs) certified for their apolipoprotein(a) [apo(a)] content. To reach measurement standardization through this new measurement system, 2 essential requirements need to be fulfilled: a sufficient correlation among the MPs and appropriate commutability of future serum-based RMs.Methods: The correlation among the candidate RMP (cRMP) and immunoassay-based MPs was assessed by measuring a panel of 39 clinical samples (CS). In addition, the commutability of 14 different candidate RMs was investigated.Results: Results of the immunoassay-based MPs and the cRMPs demonstrated good linear correlations for the CS but some significant sample-specific differences were also observed. The results of the commutability study show that RMs based on unspiked human serum pools can be commutable with CS, whereas human pools spiked with recombinant apo(a) show different behavior compared to CS.Conclusions: The results of this study show that unspiked human serum pools are the preferred candidate secondary RMs in the future SI-traceable Lp(a) Reference Measurement System.
- 16 January 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (3) , 262-272
Open AccessCommutability Assessment of Candidate Reference Materials for Lipoprotein(a) by Comparison of a MS-based Candidate Reference Measurement Procedure with Immunoassays
Background: Elevated concentrations of lipoprotein(a) [Lp(a)] are directly related to an increased risk of cardiovascular diseases, making it a relevant biomarker for clinical risk assessment. However, the lack of global standardization of current Lp(a) measurement procedures (MPs) leads to inconsistent patient care. The International Federation for Clinical Chemistry and Laboratory Medicine working group on quantitating apolipoproteins by mass spectrometry (MS) aims to develop a next-generation SI (International system of units)-traceable reference measurement system consisting of a MS-based, peptide-calibrated reference measurement procedure (RMP) and secondary serum-based reference materials (RMs) certified for their apolipoprotein(a) [apo(a)] content. To reach measurement standardization through this new measurement system, 2 essential requirements need to be fulfilled: a sufficient correlation among the MPs and appropriate commutability of future serum-based RMs.Methods: The correlation among the candidate RMP (cRMP) and immunoassay-based MPs was assessed by measuring a panel of 39 clinical samples (CS). In addition, the commutability of 14 different candidate RMs was investigated.Results: Results of the immunoassay-based MPs and the cRMPs demonstrated good linear correlations for the CS but some significant sample-specific differences were also observed. The results of the commutability study show that RMs based on unspiked human serum pools can be commutable with CS, whereas human pools spiked with recombinant apo(a) show different behavior compared to CS.Conclusions: The results of this study show that unspiked human serum pools are the preferred candidate secondary RMs in the future SI-traceable Lp(a) Reference Measurement System.
- 1 June 2021
- Published by Elsevier in Clinica Chimica Acta
- Vol. 517, 60-65
Faecal immunochemical tests for haemoglobin: Analytical challenges and potential solutions
- 1 June 2021
- Published by Elsevier in Clinica Chimica Acta
- Vol. 517, 60-65
Faecal immunochemical tests for haemoglobin: Analytical challenges and potential solutions